WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke EXOFREE wurde als Wortmarke am 23.07.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1638230 |
| Registernummer | UK00003599708 |
| Länder | 
|
| Basismarke |
Nr. UK00003599708,
02. Juli 2021
|
| Anmeldedatum | 23. Juli 2021 |
| Ablaufdatum | 23. Juli 2031 |
Markeninhaber
Oxford Science Park, Medawar Centre,
2nd Floor East Building,
GB
2nd Floor East Building,
GB
Markenvertreter
14 South Square,
Gray's Inn
GB
Waren und Dienstleistungen
05
Pharmaceuticals; pharmaceutical preparations and substances;
pharmaceutical preparations, namely, a drug delivery system
comprising genetically engineered or purified exosomes for
therapeutic use; pharmaceutical preparations, namely,
exosomes to deliver protein or nucleic acids or viral
vectors for therapy; medicine; medical preparations and
articles; biological preparations for medical purposes;
biological preparations for the treatment of cancer,
diabetes, obesity, metabolic syndrome, dementia, and other
aging associated pathologies such as mitochondrial disease,
joint/ligament strain/tears, muscle atrophy, muscular
dystrophy, neuromuscular diseases, neurological disorders,
neurodegenerative disorders, inflammatory disorders,
infectious diseases, genetic diseases, rare diseases,
in-born errors of metabolism (IEMs), lysosomal storage
disorders and urea cycle disorders; biological preparations
comprising exosome; biological preparations comprising a
therapeutic target protein-loaded, nucleic acid-loaded or
virus-loaded exosome; biological reagents for medical use;
mixed biological preparations for medical purposes; mixed
biological preparations for the prevention and treatment of
infectious diseases; pharmaceuticals, medicines, biologics,
biotherapeutics, biosimilars and therapeutics, namely,
EV-based nucleic acid therapeutics for the prevention and
treatment of infections or disease; diagnostic kits
comprised of medical diagnostic reagents and assays for
testing of bodily fluids for use in disease detection;
diagnostic kits comprised of medical diagnostic reagents and
assays for testing of exosomes for use in disease detection;
diagnostic kits comprised of medical diagnostic reagents and
assays that test for the presence of cancer, diabetes,
obesity, metabolic syndrome, dementia, and other aging
associated pathologies such as mitochondrial disease,
joint/ligament strain/tears, muscle atrophy, muscular
dystrophy, neuromuscular diseases, neurological disorders,
neurodegenerative disorders, inflammatory disorders,
infectious diseases, genetic diseases, rare diseases,
in-born errors of metabolism (IEMs), lysosomal storage
disorders and urea cycle disorders
42
Scientific, medical and pharmaceutical research and
development services; pharmaceutical drug development
services; research and development of pharmaceutical
preparations; scientific research and analysis services;
biological research; clinical research; providing medical
and scientific research information in the field of
filtration of exosomes from cultured cells or blood;
scientific investigations for medical purposes; scientific
laboratory services; medical laboratory services; laboratory
research services relating to pharmaceuticals; research and
development in the field of biotherapeutics for the
treatment of genetic diseases, cancer, diabetes, obesity,
metabolic syndrome, dementia, and other aging associated
pathologies such as mitochondrial disease, joint strain and
tears, ligament strain and tears, muscle atrophy, muscular
dystrophy, neuromuscular diseases, neurological disorders,
neurodegenerative disorders, inflammatory disorders,
infectious diseases, genetic diseases, rare diseases,
in-born errors of metabolism (IEMs), lysosomal storage
disorders and urea cycle disorders; consulting services in
the fields of biotechnology, pharmaceutical research and
development and genetic science; laboratory diagnostics;
information, advisory and consultancy services relating to
the aforesaid
44
Medical services; medical and pharmaceutical consultancy;
medical diagnostics; medical analysis and examinations;
medical treatment services; medical screening; medical
monitoring, testing, inspection and analysis services
relating to the diagnosis and treatment of cancer, viral and
bacterial based infections and diseases; medical monitoring,
testing, inspection and analysis services relating to the
diagnosis and treatment of cancer, diabetes, obesity,
metabolic syndrome, dementia, and other aging associated
pathologies such as mitochondrial disease, joint/ligament
strain/tears, muscle atrophy, muscular dystrophy,
neuromuscular diseases, neurological disorders,
neurodegenerative disorders, inflammatory disorders,
infectious diseases, genetic diseases, rare diseases,
in-born errors of metabolism (IEMs), lysosomal storage
disorders and urea cycle disorders; information, advisory
and consultancy services relating to the aforesaid
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 27. Juni 2023 | 2023/26 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 13. Oktober 2022 | 2022/41 Gaz | JP | Ablehnung |
| 26. Mai 2022 | 2022/21 Gaz | EM | Ablehnung |
| 21. April 2022 | 2022/16 Gaz | US | Ablehnung |
| 23. Juli 2021 | 2021/51 Gaz | GB | Eintragung |
ID: 141638230